Adaptive randomization of neratinib in early breast cancer

New England Journal of Medicine

Volumn 375, Issue 16, 2016, Pages 1591-1592

  Buyse, Marc ^a   Saad, Everardo D ^a   Burzykowski, Tomasz ^a  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NERATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; QUINOLINE DERIVATIVE;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG RESPONSE; EARLY CANCER; HUMAN; LETTER; PRIORITY JOURNAL; BREAST NEOPLASMS; RANDOMIZATION;

BREAST NEOPLASMS; HUMANS; QUINOLINES; RANDOM ALLOCATION; RECEPTOR, ERBB-2;

EID: 84992028261     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1609993     Document Type: Letter

References (4)

1. Harrington D, Parmigiani G. I-SPY 2 - a glimpse of the future of phase 2 drug development? N Engl J Med 2016; 375: 7-9.
2. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987; 317: 141-5.
3. Hey SP, Kimmelman J. Are outcome-adaptive allocation trials ethical? Clin Trials 2015; 12: 102-6.
4. Carey LA, Winer EP. I-SPY 2 - toward more rapid progress in breast cancer treatment. N Engl J Med 2016; 375: 83-4.